Literature DB >> 5189

Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases.

R C Jackson, L I Hart, K R Harrap.   

Abstract

Four cultured mammalian cell lines, differing in intrinsic resistance to methotrexate over a 70-fold range, have been compared with respect to several biochemical factors that might influence response to the drug. Cellular activity of the enzymes dihydrofolate reductase and thymidylate synthetase and the total levels of folate cofactors did not vary by more than a factor of 2 among the cell lines. All the cell types were able to transport extracellular methotrexate efficiently across the cell membrane, and at comparable rates. A kinetic study of highly purified dihydrofolate reductases from the four sources revealed small differences in the Km values for dihydrofolate and reduced nicotinamide adenine dinucleotide phosphate. A study was made of the inhibition of the four dihydrofolate reductases by methotrexate, and Ki values were obtained by fitting the Zone B equation of Goldstein (Goldstein, A., J. Gen. Physiol., 27: 529-580, 1944) to the resulting data. Values Ki determined by this method correlated with intrinsic resistance of the cell lines and showed a 25-fold range from the most sensitive to the most resistant line. It is concluded that the response of a cell to methotrexate is significantly influenced by the dissociation constant of its dihydrofolate reductase-methotrexate complex.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 5189

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.

Authors:  M Khorsand; J Lange; L Feun; N J Clendeninn; M Collier; G Wilding
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Role of thymidylate synthetase activity in development of methotrexate cytotoxicity.

Authors:  R G Moran; M Mulkins; C Heidelberger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

3.  A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.

Authors:  Masataka Nakano; Tatsuki Fukami; Saki Gotoh; Miki Nakajima
Journal:  J Biol Chem       Date:  2017-02-10       Impact factor: 5.157

4.  An enzyme inhibition assay for 2,4-diamino-5-(3'4'-dichlorophenyl)-6-methylpyrimidine (DDMP,NSC 19494).

Authors:  A H Calvert; J S Cridland; K R Harrap
Journal:  J Clin Pathol       Date:  1977-12       Impact factor: 3.411

5.  Mutations in the reduced-folate carrier affect protein localization and stability.

Authors:  H Sadlish; R C Murray; F M Williams; W F Flintoff
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

6.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

Authors:  Maria Maguire; Paul C Nield; Timothy Devling; Rosalind E Jenkins; B Kevin Park; Radoslaw Polański; Nikolina Vlatković; Mark T Boyd
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 7.  Clinical pharmacokinetics and pharmacology of trimetrexate.

Authors:  J L Marshall; R J DeLap
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

8.  Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.

Authors:  John C Panetta; Alex Sparreboom; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  PLoS Comput Biol       Date:  2010-12-02       Impact factor: 4.475

9.  Mathematical modeling of folate metabolism.

Authors:  John C Panetta; Steven W Paugh; William E Evans
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2013-05-22

10.  Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.

Authors:  Y Takemura; W Gibson; R Kimbell; H Kobayashi; H Miyachi; A L Jackman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.